Skip to main content
S&P 5007,744.06+0.33%DOW52,177.69+1.08%NASDAQ26,713.03+0.08%BTC$82,289.00+0.69%ETH$2,457.74+1.59%GOLD$4,190.10+2.00%OIL$96.20+2.45%
Smart Investors Daily
SID Premium
BioNTech SE logo

NASDAQ · BNTX

BioNTech SE

Healthcare · Biotechnology

$88.66

Up+$1.54 (+1.74%)

Updated Oct 15, 2026, 8:34 PM

SID Score

4.6/10

Composite research score

Smart Money

58/100

Neutral

Market cap
23.08B
P/E ratio
-57.03
Dividend yield
0.00%
52-week range
$79.52 – $124.00
Volume
1.13M
Avg. volume
1.03M

Price performance · BNTX

BNTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 14, 2026

BNTX closed at $88.66 after 21 trading sessions, down 7.48% for the selected period.

Last close
$88.66
Period change
-7.48%
Period low
$88.66
Period high
$100.87
Daily close
View OHLC price history
BNTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 14, 2026$89.01$90.50$88.57$88.661.13M
Oct 13, 2026$92.36$93.08$88.85$89.011.95M
Oct 12, 2026$97.61$98.60$95.75$95.841.28M
Oct 9, 2026$92.45$97.40$92.30$96.961.32M
Oct 8, 2026$93.81$94.45$91.64$92.061.21M
Oct 7, 2026$95.17$97.46$93.92$95.25828.08K
Oct 6, 2026$99.49$100.02$95.31$95.73899.39K
Oct 5, 2026$96.74$98.785$95.20$97.641.44M
Oct 2, 2026$97.35$97.995$96.2157$96.90696.03K
Oct 1, 2026$97.59$99.49$96.60$96.85820.11K
Sep 30, 2026$98.28$99.14$96.90$98.30845.55K
Sep 29, 2026$98.43$99.79$97.60$98.57736.95K
Sep 28, 2026$97.00$100.21$96.64$99.08785.85K
Sep 25, 2026$99.51$100.015$97.73$98.52580.03K
Sep 24, 2026$97.62$99.93$97.05$99.26803.58K
Sep 23, 2026$100.61$101.31$98.31$98.461.09M
Sep 22, 2026$98.00$102.23$97.46$100.871.05M
Sep 21, 2026$97.245$98.98$96.61$98.00801.21K
Sep 18, 2026$98.81$99.25$95.71$96.061.2M
Sep 17, 2026$97.50$99.575$97.1285$98.66708.5K
Sep 16, 2026$97.24$97.32$95.315$95.83407.6K

Latest BNTX news

The latest Smart Investors Daily articles mentioning BNTX.

Stock researchCompany · Overview

BNTX research

Overview

Company profile and research snapshot.

Company profile

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$144.75
Implied upside
—
Analysts
—
BNTX recent ratings
DateFirmRatingTarget
Oct 14, 2026Canaccord GenuityBuy—
Oct 7, 2026Morgan StanleyOverweight—
Sep 8, 2026BMO CapitalMarket Perform—
Aug 31, 2026Canaccord GenuityBuy—
Aug 5, 2026Evercore ISI GroupOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 10, 2026

Why Did BioNTech (BNTX) Move Today?

BioNTech (NasdaqGS:BNTX) last closed at US$96.96, leaving investors weighing how current pricing aligns with recent trading returns and the company’s evolving mix of oncology candidates and infectious disease programs. Recent trading has been choppy for BioNTech. The share price return over the past 90 days of 5.98% hints at some rebuilding momentum, yet the 1 year total shareholder return declined 5% and the 5 year total shareholder return fell 60.47%. This shows that longer term holders are...

Yahoo · Oct 7, 2026

Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?

BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom, which naturally puts the focus back on what investors are paying for its current and potential sales base. With market sentiment shifting around the restructuring of its manufacturing footprint and the oncology pipeline, the live question is how well the present US$95.73 price lines up with the revenue the company is generating and expects to generate. The stock has...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By